- Home
- CRNC vs MNPR Comparison
CRNC vs MNPR Comparison
Compare CRNC & MNPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CRNC | MNPR |
|---|---|---|
| Founded | 2020 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 430.2M | 368.9M |
| IPO Year | 2019 | 2019 |
Fundamental Metrics
Financial Performance| Metric | CRNC | MNPR |
|---|---|---|
| Price | $10.43 | $59.77 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 11 |
| Target Price | $10.25 | ★ $107.00 |
| AVG Volume (30 Days) | ★ 1.3M | 168.5K |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 96.95 | 54.99 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $251,781,000.00 | N/A |
| Revenue This Year | $27.18 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.85 | $29.18 |
| 52 Week High | $13.74 | $105.00 |
Technical Indicators
Market Signals| Indicator | CRNC | MNPR |
|---|---|---|
| Relative Strength Index (RSI) | 48.05 | 48.81 |
| Support Level | $9.06 | $51.32 |
| Resistance Level | $11.49 | $61.51 |
| Average True Range (ATR) | 0.94 | 4.78 |
| MACD | -0.03 | -0.49 |
| Stochastic Oscillator | 34.47 | 39.71 |
Price Performance
Historical ComparisonAbout CRNC Cerence Inc.
Cerence Inc is a United States-based software company. It is involved in developing mobility-based solutions for drivers and their cars. The customers include all automobile original equipment manufacturers, or OEMs, or their tier 1 suppliers. The company's revenue is generated by selling software licenses and cloud-connected services. Geographically, it derives a majority of its revenue from the United States and also has a presence in Other Americas; Germany; Other Europe, the Middle East, Africa; Japan, and Other Asia-Pacific.
About MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.